NL-OMON26216招募中不适用
Everolimus-eluting Bioresorbable Scaffolds for Treatment of Coronary Artery Disease in Patients with Diabetes Mellitus.International, Multicenter, Observational, Prospective Registry Study
Isala Clinics Zwolle0 个研究点目标入组 500 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients aged 18 years or older.
- •History of DM
排除标准
- •Patients unable to provide informed consent
研究者
相似试验
终止
不适用
Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total OcclusionCoronary Artery DiseaseNCT02739685University of Luebeck17
终止
4 期
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery DiseasePercutaneous Transluminal Coronary AngioplastyNCT02831205Duk-Woo Park, MD800
已完成
2 期
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers.polycystic liver disease10019654NL-OMON32654niversitair Medisch Centrum Sint Radboud44
进行中（未招募）
1 期
Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers. - ELATEIsolated polycystic liver diseaseMedDRA version: 12.1Level: LLTClassification code 10048834Term: Polycystic liver diseaseMedDRA version: 12.1Level: PTClassification code 10048834Term: Polycystic liver diseaseEUCTR2009-016640-39-NLRadboud University Nijmegen Medical Centre44
进行中（未招募）
1 期
EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 - an investigtor initiated Phase II study.• Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung• Well to moderately differentiated neuroendocrine carcinoma (NET G1/G2) that switched to G3 (confirmed by histology)• Neuroendocrine tumor G3 (NET G3)EUCTR2012-004550-28-DEAIO-Studien-gGmbH